CADTH Canadian Drug Expert Committee recommendation. indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) :
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534395/ Full text |
|---|---|
| Corporate Author: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Edition: | Version 1.0. |
| Series: | Common drug review clinical review report.
|
| Subjects: |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | p2436549 | ||
| 005 | 20240212122435.0 | ||
| 006 | m o d | ||
| 007 | cr cn |||||||| | ||
| 008 | 190102s2017 onc o 000 0 eng | ||
| 035 | |a (DNLM)BKSHLF:NBK534395 | ||
| 035 | |9 101740809 | ||
| 035 | |a 1740809 | ||
| 040 | |a DNLM |b eng |e rda |c DNLM |d UtOrBLW | ||
| 041 | 0 | 9 | |a eng |
| 042 | |a pcc | ||
| 043 | |a n-cn--- | ||
| 044 | |9 Canada | ||
| 060 | 0 | 0 | |a WL 360 |
| 110 | 2 | |a CADTH Canadian Drug Expert Committee, |e author. |0 n 2019180882 | |
| 245 | 1 | 0 | |a CADTH Canadian Drug Expert Committee recommendation. |p Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : |b indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features. |
| 246 | 1 | |a Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) | |
| 246 | 1 | |a Drug reimbursement recommendation ocrelizumab (Ocrevus) | |
| 250 | |a Version 1.0. | ||
| 264 | 1 | |a Ottawa (ON) : |b Canadian Agency for Drugs and Technologies in Health, |c November 21, 2017. | |
| 300 | |a 1 online resource (1 PDF file (8 pages)). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a CADTH common drug review | |
| 500 | |a "Final." | ||
| 520 | 3 | |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features. | |
| 536 | |a Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. | ||
| 588 | |a Description based on online resource; title from PDF title page (viewed March 5, 2019). | ||
| 650 | 1 | 2 | |a Multiple Sclerosis, Relapsing-Remitting |x drug therapy. |0 D020529Q000188 |
| 650 | 2 | 2 | |a Antibodies, Monoclonal, Humanized |x therapeutic use. |0 D061067Q000627 |
| 650 | 2 | 2 | |a Immunologic Factors |x therapeutic use. |0 D007155Q000627 |
| 650 | 2 | 2 | |a Antibodies, Monoclonal, Humanized |x economics. |0 D061067Q000191 |
| 650 | 2 | 2 | |a Cost-Benefit Analysis. |0 D003362 |
| 650 | 2 | 2 | |a Insurance, Health, Reimbursement. |0 D007349 |
| 651 | 2 | |a Canada. |0 D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e issuing body. |0 n 2007182676 | |
| 830 | 0 | |a Common drug review clinical review report. |0 n 2014186107 | |
| 856 | 4 | 0 | |u http://www.ncbi.nlm.nih.gov/books/NBK534395/ |t 0 |
| 951 | |a 2436549 | ||
| 993 | |a CAD |b 20190213 | ||
| 998 | |a BKSHLF |b 20190102 | ||
| 998 | |a FER |b 20190102 | ||
| 999 | |a AUTH | ||
| 999 | f | f | |i ef638e7e-ff03-56d7-931a-0aff43e69115 |s 5738b6ab-9fd6-54ab-916c-4b8e84183240 |t 0 |
| 952 | f | f | |a Massachusetts College of Pharmacy and Health Sciences |b Online |c Online |d E-Collections |t 0 |e NCBI |h Other scheme |
| 856 | 4 | 0 | |t 0 |u https://www.ncbi.nlm.nih.gov/books/NBK534395/ |y Full text |
